Nasus Pharma Welcomes Eyal Rubin as CFO
Nasus Pharma Ltd. (NYSE:NSRX), a company dedicated to nurturing innovative intranasal medical treatments, has appointed Eyal Rubin as its Executive Vice President and Chief Financial Officer. With over 20 years of experience in the biotechnology and pharmaceutical industries, Mr. Rubin is poised to strengthen the company's financial leadership.
Expertise in Financial Leadership
In his new role, Eyal Rubin will lead Nasus Pharma's financial operations, managing everything from corporate finance to investor relations. His extensive expertise aims to advance the company's pipeline of intranasal therapeutics, which are at the heart of their urgent medical care innovations.
Comments from Leadership
CEO Dan Teleman expressed enthusiasm about Rubin's joining the company. He noted, "We believe his robust financial knowledge and deep understanding of capital markets will significantly benefit us during this growth phase." Telman believes the timing aligns perfectly with Nasus Pharma's aspirations to enhance its product offerings.
Valuable Experience Brought to the Team
Udi Gilboa, the Executive Chairman of Nasus Pharma, conveyed confidence in Rubin's capabilities, stating, "His background in both emerging biotech and established pharmaceutical firms will be an asset as we build our operational strength." The leadership team anticipates that Mr. Rubin’s insights will facilitate the strategic execution of their clinical programs.
Prior Accomplishments of Eyal Rubin
Before joining Nasus Pharma, Eyal Rubin served as CFO and Senior Vice President at Protalix BioTherapeutics, Inc. There, he honed his skills in financial strategy and capital market communications. His previous roles also include financial leadership at BrainStorm Cell Therapeutics, Inc., and strategic treasury management at Teva Pharmaceutical Industries Ltd.
Innovations in Drug Delivery
Nasus Pharma focuses on revolutionary intranasal drug delivery technologies designed to address acute medical conditions with rapid response solutions. Their product candidate, NS002, represents a needle-free alternative for patients experiencing anaphylaxis, showcasing the potential of the company's innovations.
The Future of Nasus Pharma
Mr. Rubin himself expressed enthusiasm about contributing to Nasus Pharma: "I am thrilled to join at such a transformative time. I believe that our intranasal delivery systems represent a breakthrough in addressing significant unmet medical needs. I look forward to supporting our goals for long-term growth and success."
About Nasus Pharma
Nasus Pharma is dedicated to advancing healthcare through clinical-stage products that provide effective solutions for urgent medical conditions. Their proprietary powder-based intranasal technology is specifically crafted for effective drug delivery while ensuring patient ease-of-use. For more details, please visit www.nasuspharma.com or follow them on Twitter and LinkedIn.
Frequently Asked Questions
What is Nasus Pharma's core focus?
Nasus Pharma specializes in developing innovative intranasal products for emergency medical conditions.
Who has been appointed as the new CFO?
Eyal Rubin has been appointed as the Executive Vice President and Chief Financial Officer of Nasus Pharma.
What is the significance of Mr. Rubin's experience?
His extensive financial background in biotechnology and pharmaceuticals is expected to greatly benefit Nasus Pharma as it seeks to expand its operations.
What is the company’s product candidate NS002?
NS002 is an intranasal powder Epinephrine designed as a needle-free alternative for treating anaphylaxis.
How can I learn more about Nasus Pharma?
You can find additional information on their official website at www.nasuspharma.com.
